Epigenetic age enhances eGFR-based prediction of all-cause mortality: A cross-cohort validation of a novel risk model
Clinical Nephrology · 01.08.2026 · 106 (2) · 137-149
DOI: 10.5414/cn112016 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Clinical Nephrology, erschienen am 01.08.2026. Verfasst von Xinyu Wang und 12 weiteren Autor:innen. Hauptthemen laut MEDLINE: Glomerular Filtration Rate, Epigenesis, Genetic, DNA Methylation, Renal Insufficiency, Chronic.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Wang, X., Song, L., Lv, Q., Li, L., Wang, Q., Liu, C., Chen, M., Liu, F., Yu, Y., Shen, Y., Cui, J., Zhao, Y., & Deng, Q. (2026). Epigenetic age enhances eGFR-based prediction of all-cause mortality: A cross-cohort validation of a novel risk model. Clinical Nephrology, 106(2), 137-149. https://doi.org/10.5414/cn112016
Vancouver
Wang X, Song L, Lv Q, Li L, Wang Q, Liu C, et al. Epigenetic age enhances eGFR-based prediction of all-cause mortality: A cross-cohort validation of a novel risk model. Clinical Nephrology. 2026;106(2):137-149. doi:10.5414/cn112016
BibTeX
@article{Wang2026,
author = {Wang, Xinyu and Song, Lu and Lv, Qin and Li, Li and Wang, Qiao and Liu, Chunli and Chen, Meiyu and Liu, Feifei and Yu, Yaling and Shen, Ying and Cui, Jianchen and Zhao, Yaxi and Deng, Qinyuan},
title = {Epigenetic age enhances eGFR-based prediction of all-cause mortality: A cross-cohort validation of a novel risk model},
journal = {Clinical Nephrology},
year = {2026},
volume = {106},
number = {2},
pages = {137--149},
doi = {10.5414/cn112016}
}
EUVIMED